VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
LH
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
LHLabcorp Holdings Inc.
$368.24$30.2B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
LH logo

Labcorp Holdings Inc.

LH
NYSE · Diagnostics & Lab Testing
$368.24
At close - Nov 17, 4:00 PM EST - USD
Market Cap$30.2B
P/E29.9x
52W High$375.10
Volume715.27K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q3

Steady Diagnostics Growth Offset by Leverage and Cash Volatility

Labcorp's revenue grew 6.9% year over year to $3.8B in Q3 2026, and gross margin recovered from 26.2% in Q4 2025 to 29.1%, suggesting steady underlying demand across its diagnostics base.

GrowthStable
ProfitabilityModerate
ValuationAttractive
TechnicalsStrong
Explore valuation models
MARKET ACTION

LH price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

12/12 Beats

EPS beat 12 of last 12 quarters

02

Valuation risk

-15% Peers

P/E is 15% below peer median

03

Market leadership

RS 89 · Leader

High momentum (Outperforming 89% of market)

04

Strong Uptrend

Strong Trend

Price > 20DMA > 50DMA > 200DMA

Next CatalystEstimated earnings · Jan 28
01

Build the investment case

Start with the evidence for owning the stock and the risks that can break the thesis.

EXECUTIVE THESIS

The Investment Case

Full Analysis
Fundamental Trajectory

Revenue reached $3.8B with a 6.9% net margin in Q3 2026, but operating margin compressed to 10.6% from 12.1% in the prior quarter, suggesting margin recovery remains fragile.

Analyst Consensus+5.9% target
Buy(35 analysts)
26 Buy9 Hold0 Sell

The Bull Case

Upside Catalysts

AI-powered data platform

Labcorp's collaboration with AWS and Datavant has created an AI-driven platform that leverages longitudinal laboratory data and advanced analytics to accelerate drug discovery and streamline processes.

Comprehensive healthcare services

Labcorp provides end-to-end drug development and clinical laboratory services, positioning it as a leader in guiding patient care and life sciences innovation.

Genomic testing pioneer

The company has a strong legacy in genomic testing, including early adoption of PCR technology, enhancing its credibility and capabilities in molecular biology and pathology.

The Bear Case

Key Downside Risks

Market performance

Price History →

Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
LH+47.18%
S&P 500 (^GSPC)+7.21%
1-Year Return
LH+41.99%
S&P 500 (^GSPC)+10.03%
3-Year Return
LH+77.67%
S&P 500 (^GSPC)+59.83%
5-Year Return
LH+52.95%
S&P 500 (^GSPC)+54.02%
02

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis
Trailing P/E5Y High
29.9x
Forward P/EExpansion
19.9x
EV/EBITDA80th %ile
15.8x
FCF YieldCash Flow
4.3%

Valuation vs 5-Year History

Multiple Range
Metric
Current
5Y Median
Historical Range
Percentile
P/E
29.9x
24.0x
80th· High
EV/EBITDA
15.8x
12.6x
80th· High
Price/FCF
23.5x
17.4x
100th· High
Current Multiple
5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection
Bear$211.50-42.6%
Base (Fair)$443.02+19.6%
Bull$813.15+120.8%
$211.50 Bear$443.02 Base$813.15 Bull
Current Market Price: $368.24
Trades at a 16.9% discount to Base DCF ($443.02)
Open DCF & Valuation Models →Chart Terminal ↗

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$13.95B+7.2% YoY
Net income FY25
$877M+17.5% YoY
Free cash flow FY25
$1.21B+10.0% YoY
Operating margin FY25
10.9%+2.5 pts YoY
ROIC (FY25)7.8%
Avg ROIC 5Y7.9%
ROE (TTM)11.5%
Piotroski Score7 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate12/12 (100%)
Revenue Beat Rate10/12 (83%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Oct 28, 2026
$4.78+3.0%
vs $4.64
$3.8B+1.4%
vs $3.8B
Q3 2026
Jul 30, 2026
$4.99+4.4%
vs $4.78
$3.7B+0.6%
vs $3.7B
Q2 2026
Apr 30, 2026
$4.25+3.4%
vs $4.11
$3.5B+0.8%
vs $3.5B
Q1 2026
Feb 17, 2026
$4.07+3.0%
vs $3.95
$3.5B-1.2%
vs $3.6B
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
PRNewsWire·19h ago
Labcorp to Expand Clinical Trial Operations in Brazil with Dedicated Kit Assembly and Future Laboratory Operations through Collaboration with Grupo Fleury

Expansion will bring clinical trial services closer to research sites and patients while supporting global studies BURLINGTON, N.C., Nov. 17, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced a collaboration with Grupo Fleury, one of Brazil's leading healthcare and diagnostic groups, with extensive laboratory infrastructure, scientific expertise and a strong presence across the Brazil healthcare ecosystem, to expand clinical trial operations in the country.

Zacks Investment Research·1d ago
Why Labcorp Holdings (LH) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Defense World·2d ago
Labcorp (NYSE:LH) EVP Sells $744,080.00 in Stock

Labcorp Holdings Inc. (NYSE: LH - Get Free Report) EVP Brian Caveney sold 2,000 shares of the stock in a transaction on Tuesday, November 10th. The shares were sold at an average price of $372.04, for a total value of $744,080.00. Following the completion of the transaction, the executive vice president directly owned 34,562 shares of

Defense World·2d ago
Fifth Third Bancorp Sells 6,956 Shares of Labcorp Holdings Inc. $LH

Fifth Third Bancorp lessened its position in Labcorp Holdings Inc. (NYSE: LH) by 12.4% during the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 49,116 shares of the medical research company's stock after selling 6,956 shares during the period. Fifth Third

Filtered for Labcorp Holdings Inc.More Headlines
04

Compare before deciding

Benchmark LH against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Labcorp Holdings Inc. (LH)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
LH logoLHLabcorp Holdings Inc.Current
$368.24$30.2B29.937.25%6.88%11.52%0.78%
DGX logoDGXQuest Diagnostics Incorporated
$256.35$28.29B25.4311.78%9.53%14.66%1.22%
BIO logoBIOBio-Rad Laboratories, Inc.
$358.19$9.64B9.440.65%39.45%14.07%—
NTRA logoNTRANatera, Inc.
$287.47$41.17B-251.4435.9%-5.66%-9.18%—
IQV logoIQVIQVIA Holdings Inc.
$257.60$42.4B30.865.87%8.05%21.39%—
CRL logoCRLCharles River Laboratories International, Inc.
$332.16$16B401.55-0.85%1.01%1.3%—

Compare LH vs Peers

Labcorp Holdings Inc. (LH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs DGX

Most directly comparable listed peer for LH.

Scale Benchmark

vs TMO

Larger-name benchmark to compare LH against a more recognizable public peer.

Peer Set

Compare Top 5

vs DGX, BIO, NTRA, IQV

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

LH SEC Filings & Documents

Labcorp Holdings Inc. (LH) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Oct 28, 2026·SEC

Material company update

Oct 21, 2026·SEC

Material company update

Sep 30, 2026·SEC

10-K Annual Reports

2
FY 2026

Feb 24, 2026·SEC

FY 2025

Feb 25, 2025·SEC

10-Q Quarterly Reports

6
FY 2026

Oct 30, 2026·SEC

FY 2026

Aug 5, 2026·SEC

FY 2026

May 4, 2026·SEC

Get notified when LH posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

LH Frequently Asked Questions

Labcorp Holdings Inc. (LH) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Labcorp Holdings Inc.'s revenue?

Labcorp Holdings Inc. (LH) reported $14.59B in revenue over the trailing twelve months. Revenue was $13.95B in fiscal year 2025. That is 768% more than the $1.61B of fiscal year 1996.

How fast is Labcorp Holdings Inc. growing?

Labcorp Holdings Inc. (LH) grew revenue by 6.0% over the trailing twelve months, compared with the twelve months before.

Is LH profitable?

Yes. Labcorp Holdings Inc. (LH) earned $1.00B in net income over the trailing twelve months (a 6.9% net margin).

Dividend & Returns
Does LH pay dividends?

Yes. Labcorp Holdings Inc. (LH) pays a dividend that yields 0.78% at the current price, a small yield.

What is LH's return on equity?

Labcorp Holdings Inc. (LH) had a return on equity (ROE) of 11.5% over the trailing twelve months. That is in line with the market's typical 10-15%.

What is Labcorp Holdings Inc.'s free cash flow?

Labcorp Holdings Inc. (LH) generated $1.29B in free cash flow over the trailing twelve months.

What if you invested $1,000 in LH back in 1996?

Total return calculator · dividends reinvested · 30+ years of data

See returns →